Tags

Type your tag names separated by a space and hit enter

Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice.
Viral Immunol. 2016 05; 29(4):228-34.VI

Abstract

Influenza is an acute and highly contagious respiratory disease. The error prone RNA polymerase and segmented nature of the influenza A virus genome allow antigenic drift and shift, respectively. Therefore, most influenza vaccines are inefficient along time and against different viral subtypes. In this study, for the first time, protection properties of a new recombinant fusion of HA2 and M2e peptides originated from influenza virus A/Brisbane/59/2007-like (H1N1) in BALB/c mice model were investigated. After immunization of the BALB/c mice, the protection property of fusion peptide was determined by a neutralizing assay test. For further study, mice were lethal challenged by the (mouse adapted, A/PR8/34 [H1N1]) and heterologous (mouse adapted, A/Brisbane/10/2007 [H3N2]) influenza virus subtypes. Then, the lung viral titers, body weight, and survival rate of the immunized mice were monitored. The results showed that immunization by the M2e-HA2 recombinant fusion peptide provides strong protection against homologous challenge and an infirm protection against heterologous. These protections against homologous and heterologous influenza A virus challenges meant the universal nature of these recombinant peptides in an immunity manner against influenza A virus. However, more studies are needed to optimize this recombinant construction, and this experiment recommends HA2-M2e fusion peptide as a universal influenza A vaccine candidate.

Authors+Show Affiliations

1 Immunology Research Center, Tabriz University of Medical Sciences , Tabriz, Iran . 2 Department of Influenza Vaccine Research, Razi Vaccine and Serum Research Institute , Alborz, Iran . 3 Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran .1 Immunology Research Center, Tabriz University of Medical Sciences , Tabriz, Iran . 4 Department of Medical Biotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences , Tabriz, Iran .1 Immunology Research Center, Tabriz University of Medical Sciences , Tabriz, Iran .5 Research Institute for Fundamental Sciences (RIFS), University of Tabriz , Tabriz, Iran .2 Department of Influenza Vaccine Research, Razi Vaccine and Serum Research Institute , Alborz, Iran . 6 Department of Virology, Faculty of Medicine, Iran University of Medical Science , Tehran, Iran .1 Immunology Research Center, Tabriz University of Medical Sciences , Tabriz, Iran . 3 Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran . 4 Department of Medical Biotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences , Tabriz, Iran .7 Department of Genomics and Genetic Engineering, Razi Vaccine and Serum Research Institute , Alborz, Iran .

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27058011

Citation

Ameghi, Ali, et al. "Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge By Immunization With New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice." Viral Immunology, vol. 29, no. 4, 2016, pp. 228-34.
Ameghi A, Pilehvar-Soltanahmadi Y, Baradaran B, et al. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice. Viral Immunol. 2016;29(4):228-34.
Ameghi, A., Pilehvar-Soltanahmadi, Y., Baradaran, B., Barzegar, A., Taghizadeh, M., Zarghami, N., & Aghaiypour, K. (2016). Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice. Viral Immunology, 29(4), 228-34. https://doi.org/10.1089/vim.2015.0050
Ameghi A, et al. Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge By Immunization With New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice. Viral Immunol. 2016;29(4):228-34. PubMed PMID: 27058011.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Protective Immunity Against Homologous and Heterologous Influenza Virus Lethal Challenge by Immunization with New Recombinant Chimeric HA2-M2e Fusion Protein in BALB/C Mice. AU - Ameghi,Ali, AU - Pilehvar-Soltanahmadi,Yones, AU - Baradaran,Behzad, AU - Barzegar,Abolfazl, AU - Taghizadeh,Morteza, AU - Zarghami,Nosratollah, AU - Aghaiypour,Khosrow, Y1 - 2016/04/08/ PY - 2016/4/9/entrez PY - 2016/4/9/pubmed PY - 2017/12/30/medline SP - 228 EP - 34 JF - Viral immunology JO - Viral Immunol VL - 29 IS - 4 N2 - Influenza is an acute and highly contagious respiratory disease. The error prone RNA polymerase and segmented nature of the influenza A virus genome allow antigenic drift and shift, respectively. Therefore, most influenza vaccines are inefficient along time and against different viral subtypes. In this study, for the first time, protection properties of a new recombinant fusion of HA2 and M2e peptides originated from influenza virus A/Brisbane/59/2007-like (H1N1) in BALB/c mice model were investigated. After immunization of the BALB/c mice, the protection property of fusion peptide was determined by a neutralizing assay test. For further study, mice were lethal challenged by the (mouse adapted, A/PR8/34 [H1N1]) and heterologous (mouse adapted, A/Brisbane/10/2007 [H3N2]) influenza virus subtypes. Then, the lung viral titers, body weight, and survival rate of the immunized mice were monitored. The results showed that immunization by the M2e-HA2 recombinant fusion peptide provides strong protection against homologous challenge and an infirm protection against heterologous. These protections against homologous and heterologous influenza A virus challenges meant the universal nature of these recombinant peptides in an immunity manner against influenza A virus. However, more studies are needed to optimize this recombinant construction, and this experiment recommends HA2-M2e fusion peptide as a universal influenza A vaccine candidate. SN - 1557-8976 UR - https://www.unboundmedicine.com/medline/citation/27058011/Protective_Immunity_Against_Homologous_and_Heterologous_Influenza_Virus_Lethal_Challenge_by_Immunization_with_New_Recombinant_Chimeric_HA2_M2e_Fusion_Protein_in_BALB/C_Mice_ L2 - https://www.liebertpub.com/doi/10.1089/vim.2015.0050?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -